Company / SG&A Expense
Dyne Therapeutics, Inc. SG&A Expense History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$62.5M
FY2024
5-year range
$13.4M / $62.5M
FY2020-FY2024
Trend
+99.0%
vs FY2023
Sector context
#142 of 211
Health Care
What the data says
At $62M, Dyne Therapeutics, Inc.'s sg&a expense ranks #70 of 211 in the Health Care sector. Increased from $28M to $62M over the past 2 years.
Based on SEC 10-K filings.
$62M in FY2024 with a 5-year CAGR of +86.3%.
Increased from $28M to $62M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +29.6%
- 5-Year CAGR
- +86.3%
- 10-Year CAGR
- -
Sector benchmark
#70 of 211 in Health CareTop 33% of 211This company $62.5M Sector average $728.7M
▼
-91.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +86.3%, indicating consistent growth.
- In FY2024, sg&a expense increased 99.0% year-over-year.
- Ranks #142 out of 211 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $62.5M | +99.0% |
| FY2023 | $31.4M | +11.3% |
| FY2022 | $28.2M | -1.8% |
| FY2021 | $28.7M | +113.6% |
| FY2020 | $13.4M | +382.7% |
| FY2019 | $2.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026